Open AccessBehavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid
Author(s) -
Jonathan Savitz,
Bart N. Ford,
HungWen Yeh,
Elisabeth Akeman,
Kelly T. Cosgrove,
Ashley Clausen,
Christopher R. Martell,
Namik Kirlić,
Jessica Santiago,
T. Kent Teague,
Michael R. Irwin,
Martin P. Paulus,
Robin L. Aupperle
Publication year - 2020
Publication title -
psychological medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.857
H-Index - 209
eISSN - 1469-8978
pISSN - 0033-2917
DOI - 10.1017/s0033291720004389
Subject(s) - quinolinic acid , behavioral activation , depression (economics) , psychology , medicine , clinical psychology , psychiatry , psychotherapist , endocrinology , chemistry , biochemistry , cognition , tryptophan , amino acid , economics , macroeconomics
An inflammation-induced imbalance in the kynurenine pathway (KP) has been reported in major depressive disorder but the utility of these metabolites as predictive or therapeutic biomarkers of behavioral activation (BA) therapy is unknown.